GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Sensorion SA (XPAR:ALSEN) » Definitions » Net Investment Income

Sensorion (XPAR:ALSEN) Net Investment Income


View and export this data going back to 2015. Start your Free Trial

What is Sensorion Net Investment Income?

Net Investment Income only applies to insurance companies.


Sensorion (XPAR:ALSEN) Business Description

Traded in Other Exchanges
Address
375, rue du Professeur Joseph Blayac, Montpellier, FRA, 34080
Sensorion SA is a France-based clinical-stage biotech company dedicated to the development of therapies to restore, treat and prevent hearing loss. The company's product is in phase 2 clinical development, SENS-401 (Arazasetron) in Sudden Sensorineural Hearing Loss (SSNHL). SENS-401 is being developed to treat cochlear pathologies.